In colorectal cancer (CT26) BALB/c models, combination of the AOS001F/5-FC with anti-PD-1 therapy resulted in both an elevated CD4+ T cells at the tumor site and an increased the CD8/T reg ratio [373]. Here, CD4 is linked to neoplasm.